Imaging With [89Zr]Panitumumab-PET/MRI in Patients With Newly Diagnosed Colorectal Cancer

• Status: Recruiting
• Trial end date: 2026-01-01
• Target enrollment: 0
• Participant gender: All

Summary

This clinical study will investigate the utility of PET imaging with [89Zr]Panitumumab for imaging of EGFR expression in newly diagnosed colon cancer patients to assess lymph node involvement. If promising, this data will be used to design larger trials.

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Alabama at Birmingham
• Treatments: Antibodies, Monoclonal; Panitumumab

Criteria

Inclusion Criteria:

• Be at least 19 years of age.

• Diagnosis of colon cancer

• Scheduled to undergo surgical resection

Exclusion Criteria:

• Inability to provide informed consent

• Pregnancy

• Inability to lie still for the imaging study

• Weight over 350 lbs., due to the scanner bore size

• Contraindication for MRI study (e.g. non-removable metal implants or certain tattoos)

• Inability to receive Omnipaque (iohexol) iodinated contrast

• Inability to receive glucagon

• Inability to receive Eovist (gadoxetate disodium) gadolinium based contrast agent

• Allergy to contrast imaging agents

• Finding or suspicion of distant metastases on CT